Cargando…

TET2 deficiency promotes MDS-associated leukemogenesis

Detalles Bibliográficos
Autores principales:	Huang, Feiteng, Sun, Jie, Chen, Wei, Zhang, Lei, He, Xin, Dong, Haojie, Wu, Yuhui, Wang, Hanying, Li, Zheng, Ball, Brian, Khaled, Samer, Marcucci, Guido, Li, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532431/ https://www.ncbi.nlm.nih.gov/pubmed/36195586 http://dx.doi.org/10.1038/s41408-022-00739-w

Ejemplares similares

Correction: TET2 deficiency promotes MDS-associated leukemogenesis
por: Huang, Feiteng, et al.
Publicado: (2023)

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
por: Huang, Feiteng, et al.
Publicado: (2020)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models
por: Ono, Ryoichi, et al.
Publicado: (2021)

Il-1r1 drives leukemogenesis induced by Tet2 loss
por: Burns, Sarah S., et al.
Publicado: (2022)

Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis
por: Rasmussen, Kasper D., et al.
Publicado: (2015)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

The Philadelphia chromosome in leukemogenesis
por: Kang, Zhi-Jie, et al.
Publicado: (2016)

Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis
por: Zhang, Qi, et al.
Publicado: (2022)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

The process of leukemogenesis.
por: Irons, R D, et al.
Publicado: (1996)

Protein arginine methyltransferase 1 is required for maintenance of normal adult hematopoiesis
por: Zhu, Lei, et al.
Publicado: (2019)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
por: Gregory, Gareth P., et al.
Publicado: (2019)

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
por: Huber, Sandra, et al.
Publicado: (2022)

Fit αβ T-cell receptor suppresses leukemogenesis of Pten-deficient thymocytes
por: Gon, Stéphanie, et al.
Publicado: (2018)

Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients
por: Balducci, Estelle, et al.
Publicado: (2022)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

Editorial: Mechanisms of Epigenetics and Genetics in Leukemogenesis
por: Li, Yonghui, et al.
Publicado: (2022)

Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis
por: Wang, Zhengqi, et al.
Publicado: (2015)

RelB-Dependent Stromal Cells Promote T-Cell Leukemogenesis
por: dos Santos, Nuno R., et al.
Publicado: (2008)

Leukemogenesis and ageing: ‘fit for transformation’ ?
por: Greaves, Mel
Publicado: (2011)

Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL
por: Chen, Long, et al.
Publicado: (2023)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Impaired DNA Replication within Progenitor Cell Pools Promotes Leukemogenesis
por: Bilousova, Ganna, et al.
Publicado: (2005)

Role of Nucleophosmin Gene Mutation in Leukemogenesis of Acute Myeloid Leukemia
por: Khaled, Safaa A.A., et al.
Publicado: (2018)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Mesenchymal niche: the sensor and effector of leukemogenesis
por: Oh, Il-Hoan
Publicado: (2015)

The Role of TAL1 in Hematopoiesis and Leukemogenesis
por: Vagapova, E. R., et al.
Publicado: (2018)

A Prospective Analysis of Human Leukemogenesis
por: Eaves, Connie J.
Publicado: (2018)

NSD1 in erythroid differentiation and leukemogenesis
por: Tauchmann, Samantha, et al.
Publicado: (2020)

H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia
por: Zhang, Ting-juan, et al.
Publicado: (2018)

PML nuclear body biogenesis and oligomerization-driven leukemogenesis
por: Li, Yuwen, et al.
Publicado: (2020)

The Deficiency of Tumor Suppressor Prep1 Accelerates the Onset of Meis1- Hoxa9 Leukemogenesis
por: Dardaei, Leila, et al.
Publicado: (2014)

Maintenance of the functional integrity of mouse hematopoiesis by EED and promotion of leukemogenesis by EED haploinsufficiency
por: Ikeda, Kenichiro, et al.
Publicado: (2016)

The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis
por: Liu, Lulu, et al.
Publicado: (2018)

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
por: Zhu, Xiao-Na, et al.
Publicado: (2023)

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer
por: Meng, Hui, et al.
Publicado: (2022)

Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: a case report
por: Chen, Yujie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0dsdvdchj0gpmgivirmjklaeg4